ShareValue scores for AARD: Valuation 51, Quality 55, Growth 58, Health 53.
AARDNASDAQ
Aardvark Therapeutics, Inc. Common Stock
$7.30
(-2.93%)
AARDNASDAQ
Aardvark Therapeutics, Inc. Common Stock
$7.30(-2.93%)
Loading chart...
Sentiment
Verdicts
Value:Fair Value
Quality:Moderate
Growth:Moderate
Health:Moderate
Verdicts
Fundamental Rating
Value Trap Risk
Expected Return
7% to 17%
Rating
Trap Risk
Return
7% to 17%
Valuation
51
Fair Value
Price vs Value
Quality
55
Moderate
Business Strength
Growth
58
Moderate
Revenue & Earnings
Health
53
Moderate
Financial Stability
Momentum
47
Neutral
Price Trend
Company Details
About
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
Market Cap$159M
P/E RatioN/A
Dividend YieldNone
Sector Rank#723
Score Analysis
AI Investment Thesis
Data as of:Aug 7, 2026
|Last calculated:Aug 7, 2026